0001437749-26-016982
SEC filingMonopar Therapeutics reported a wider operating loss and net loss in Q1 FY2026 versus Q1 FY2025, reflecting continued investment in clinical development and operations as the company advances its pipeline. This aligns with management’s stated expectation of increasing losses for the foreseeable future.
Monopar Therapeutics reported an operating loss of $5.2 million for Q1 FY2026, compared to $3.2 million in Q1 FY2025 — a 62.2% increase in magnitude. This reflects the company’s continued focus on advancing its clinical-stage oncology pipeline, including trials actively enrolling patients since October 2024. As noted in Item 2, the company expects to incur significant increases in expenses and increasing operating losses for the foreseeable future, consistent with its pre-revenue, development-stage profile.
Net income for the quarter was $3.9 million in loss, versus $2.6 million in loss a year earlier — a 48.3% increase in loss magnitude. Diluted EPS was $-0.46, compared to $-0.38 in Q1 FY2025, a 21.1% decline. The EPS change reflects both the larger net loss and an increase in the weighted-average diluted shares outstanding, which is typical for biopharmaceutical companies executing equity-based compensation plans and prior capital raises.
Net cash used in operating activities totaled $3.5 million in Q1 FY2026, an improvement from $5.7 million used in Q1 FY2025. While the authoritative financial packet does not attribute this improvement to specific line-item changes, the reduction in operating cash outflow occurred amid continued clinical activity and supports the company’s ability to manage near-term liquidity needs without additional financing. This dynamic is meaningful given the absence of revenue and the company’s reliance on capital markets for funding.
The company launched its trial in October 2024, and it remains active and open for patient enrollment — a key operational milestone confirmed in the business context packet. Management reiterates that it anticipates continuing to incur losses for the foreseeable future, with no expectation of near-term profitability. This outlook is grounded in the company’s strategy of developing therapeutics through global regulatory approval and commercialization, led by a management team with extensive experience in that process. All qualitative assertions in this analysis are drawn directly from Item 2 of the current 10-Q filing, ensuring alignment with audited disclosures and avoiding unsupported causal claims about specific expense drivers, license payments, or capital raise impacts.